STRO vs XOM · rev $62.0M vs P/E 24, rev $332.24B
Sutro Biopharma (STRO) versus Exxon Mobil Corp (XOM) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Exxon Mobil Corp (XOM) is a oil & gas integrated company listed on NYSE. It is led by Darren Woods.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported XOM revenue for 2025-12-31 was $332.24B. Net income was $28.84B. Revenue was down 5.0% from 2024-12-31 to 2025-12-31. XOM currently screens at market cap $583.36B and trailing P/E 23.7.
STRO currently screens at market cap $470.8M. XOM currently screens at market cap $583.36B and trailing P/E 23.7.
Not investment advice. Open the STRO and XOM stock pages for the full models.
Not investment advice.